FDA — authorised 5 June 1965
- Marketing authorisation holder: MEDA PHARMS
- Status: approved
FDA authorised Avc on 5 June 1965
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 5 June 1965; FDA authorised it on 19 September 1985.
MEDA PHARMS holds the US marketing authorisation.